Folgen
Ylenia Perone
Titel
Zitiert von
Zitiert von
Jahr
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
LM Butler, Y Perone, J Dehairs, LE Lupien, V de Laat, A Talebi, M Loda, ...
Advanced drug delivery reviews 159, 245-293, 2020
1762020
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
DK Patten, G Corleone, B Győrffy, Y Perone, N Slaven, I Barozzi, E Erdős, ...
Nature medicine 24 (9), 1469-1480, 2018
992018
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation
RS Auriemma, Y Perone, A Di Sarno, LFS Grasso, E Guerra, M Gasperi, ...
The Journal of Clinical Endocrinology & Metabolism 98 (1), 372-379, 2013
932013
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
L Magnani, G Frige, RM Gadaleta, G Corleone, S Fabris, H Kempe, ...
Nature genetics 49 (3), 444-450, 2017
802017
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas
RS Auriemma, R Pivonello, Y Perone, LFS Grasso, L Ferreri, C Simeoli, ...
European journal of endocrinology 169 (3), 359-366, 2013
712013
Effect of cabergoline on metabolism in prolactinomas
RS Auriemma, L Granieri, M Galdiero, C Simeoli, Y Perone, P Vitale, ...
Neuroendocrinology 98 (4), 299-310, 2013
712013
SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Y Perone, AJ Farrugia, A Rodríguez-Meira, B Győrffy, C Ion, A Uggetti, ...
Nature communications 10 (1), 1-15, 2019
392019
Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias
RS Auriemma, R Pivonello, MC De Martino, G Cudemo, LFS Grasso, ...
European Journal of Endocrinology 168 (1), 15-22, 2013
342013
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma
A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ...
Cancers 14 (1), 186, 2021
112021
Going off the grid: ERα breast cancer beyond estradiol
Y Perone, L Magnani
Journal of Molecular Endocrinology 57 (1), F1-F5, 2016
42016
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
L Garrigós, C Saura, C Martinez-Vila, A Zambelli, M Bower, B Pistilli, ...
Therapeutic Advances in Medical Oncology 13, 17588359211053416, 2021
22021
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Y Perone, AJ Farrugia, A Rodríguez-Meira, B Győrffy, C Ion, A Uggetti, ...
Nature Communications 10 (1), 1-1, 2019
12019
Journal club: epigenetic profiling to classify cancer of unknown primary
Y Perone, FM Fioretti
The Lancet Oncology 18 (3), e130, 2017
12017
Impact of COVID19 on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study
S De Souza, JK de Long, Y Perone, S Shetty, M Qurashi, R Jones, V Yip, ...
2022
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma
C Fulgenzi, A Muhammed, S Dharmapuri, M Pinter, L Balcar, B Scheiner, ...
Journal of Hepatology 77, S372-S373, 2022
2022
Abstract P4-07-06: Breast cancer subtype classification using NanoString and RNAseq technologies
A Rocca, S Ravaioli, E Fonzi, I Barozzi, Y Perone, L Magnani, F Pirini, ...
Cancer Research 80 (4_Supplement), P4-07-06-P4-07-06, 2020
2020
OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer
Y Perone, A Rodríguez Meira, A Farruggia, B Győrffy, C Ion, G Pruneri, ...
Journal of the Endocrine Society 3 (Supplement_1), OR34-2, 2019
2019
The role of SREBP1 in hormone-dependent breast cancer
Y Perone
Imperial College London, 2019
2019
PO-357 SREBP1 drives cell-autonomous cytoskeletal changes by KRT80 remodelling during ERα breast cancer progression
Y Perone, AR Meira, A Farruggia, B Győrffy, C Ion, G Pruneri, A Lim, ...
ESMO Open 3, A161-A162, 2018
2018
PO-355 Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
L Magnani, D Patten, G Corleone, Y Perone, N Slaven, I Barozzi, ...
ESMO Open 3, A161, 2018
2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20